A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects
Abstract
:1. Introduction
2. Results
2.1. Compound 25 Inhibited STAT3-Based Luciferase Activity and Tumor Cell Growth
2.2. Compound 25 Bound Directly to STAT3 SH2 Domain
2.3. Compound 25 Inhibited Constitutive and IL-6-Induced pY705-STAT3
2.4. Compound 25 Selectively Inhibited STAT3
2.5. Compound 25 Suppressed Proliferation, Survival, and Migration of Cancer Cells
2.6. Compound 25 Inhibited the Growth of A549 Xenograft Tumors
3. Discussion
4. Materials and Methods
4.1. Cell Lines and Cell Culture
4.2. Antibodies and Reagents
4.3. Gene Reporter Assay
4.4. Molecular Docking
4.5. Surface Plasmon Resonance (SPR) Analysis
4.6. Cellular Thermal Shift Assay (CETSA)
4.7. Western Blot
4.8. IL-6 Induction of STAT3 Phosphorylation
4.9. Cell Viability Assay
4.10. Colony Formation
4.11. Wound Healing Assay
4.12. In Vivo Studies
4.13. Immunohistochemistry (IHC) Analyses
4.14. Data Analysis and Statistical Methods
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hu, X.; Li, J.; Fu, M.; Zhao, X.; Wang, W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct. Target. Ther. 2021, 6, 402. [Google Scholar] [CrossRef] [PubMed]
- Dong, J.; Cheng, X.D.; Zhang, W.D.; Qin, J.J. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation. J. Med. Chem. 2021, 64, 8884–8915. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Lv, J.; Yang, W.; Xu, B.; Wang, Z.; Yu, Z.; Wu, J.; Yang, Y.; Han, Y. Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 2019, 9, 6424–6442. [Google Scholar] [CrossRef] [PubMed]
- Kim, B.H.; Yi, E.H.; Ye, S.K. Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment. Arch. Pharm. Res. 2016, 39, 1085–1099. [Google Scholar] [CrossRef]
- Thilakasiri, P.S.; Dmello, R.S.; Nero, T.L.; Parker, M.W.; Ernst, M.; Chand, A.L. Repurposing of drugs as STAT3 inhibitors for cancer therapy. Semin. Cancer Biol. 2021, 68, 31–46. [Google Scholar] [CrossRef]
- Furtek, S.L.; Backos, D.S.; Matheson, C.J.; Reigan, P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem. Biol. 2016, 11, 308–318. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Liao, S.; Bennett, S.; Tang, H.; Song, D.; Wood, D.; Zhan, X.; Xu, J. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021, 54, e12974. [Google Scholar] [CrossRef]
- Zou, S.; Tong, Q.; Liu, B.; Huang, W.; Tian, Y.; Fu, X. Targeting STAT3 in Cancer Immunotherapy. Mol. Cancer. 2020, 19, 145. [Google Scholar] [CrossRef]
- Chen, H.; Bian, A.; Yang, L.F.; Yin, X.; Wang, J.; Ti, C.; Miao, Y.; Peng, S.; Xu, S.; Liu, M.; et al. Targeting STAT3 by a small molecule suppresses pancreatic cancer progression. Oncogene 2021, 40, 1440–1457. [Google Scholar] [CrossRef]
- Roskoski, R., Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharm. Res. 2016, 111, 784–803. [Google Scholar] [CrossRef]
- Banerjee, S.; Biehl, A.; Gadina, M.; Hasni, S.; Schwartz, D.M. JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 2017, 77, 521–546. [Google Scholar] [CrossRef] [PubMed]
- Kotyla, P.J.; Engelmann, M.; Giemza-Stoklosa, J.; Wnuk, B.; Islam, M.A. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role? Int. J. Mol. Sci. 2021, 22, 2449. [Google Scholar] [CrossRef] [PubMed]
- Beebe, J.D.; Liu, J.Y.; Zhang, J.T. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharm. Ther. 2018, 191, 74–91. [Google Scholar] [CrossRef] [PubMed]
- Li, J.; Lu, D.; Liu, H.; Williams, B.O.; Overbeek, P.A.; Lee, B.; Zheng, L.; Yang, T. Sclt1 deficiency causes cystic kidney by activating ERK and STAT3 signaling. Hum. Mol. Genet 2017, 26, 2949–2960. [Google Scholar] [CrossRef] [PubMed]
- Miyoshi, K.; Takaishi, M.; Nakajima, K.; Ikeda, M.; Kanda, T.; Tarutani, M.; Iiyama, T.; Asao, N.; DiGiovanni, J.; Sano, S. Stat3 as a therapeutic target for the treatment of psoriasis: A clinical feasibility study with STA-21, a Stat3 inhibitor. J. Investig. Dermatol. 2011, 131, 108–117. [Google Scholar] [CrossRef]
- Chen, H.; Yang, Z.; Ding, C.; Xiong, A.; Wild, C.; Wang, L.; Ye, N.; Cai, G.; Flores, R.M.; Ding, Y.; et al. Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3). Eur. J. Med. Chem. 2014, 82, 195–203. [Google Scholar] [CrossRef] [PubMed]
- Jung, K.H.; Yoo, W.; Stevenson, H.L.; Deshpande, D.; Shen, H.; Gagea, M.; Yoo, S.Y.; Wang, J.; Eckols, T.K.; Bharadwaj, U.; et al. Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice. Clin. Cancer Res. 2017, 23, 5537–5546. [Google Scholar] [CrossRef]
- Hatiboglu, M.A.; Kong, L.Y.; Wei, J.; Wang, Y.; McEnery, K.A.; Fuller, G.N.; Qiao, W.; Davies, M.A.; Priebe, W.; Heimberger, A.B. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int. J. Cancer 2012, 131, 8–17. [Google Scholar] [CrossRef]
- Jonker, D.J.; Nott, L.; Yoshino, T.; Gill, S.; Shapiro, J.; Ohtsu, A.; Zalcberg, J.; Vickers, M.M.; Wei, A.C.; Gao, Y.; et al. Napabucasin versus placebo in refractory advanced colorectal cancer: A randomised phase 3 trial. Lancet Gastroenterol. Hepatol. 2018, 3, 263–270. [Google Scholar] [CrossRef]
- Liang, X.; Luo, D.; Luesch, H. Advances in exploring the therapeutic potential of marine natural products. Pharm. Res. 2019, 147, 104373. [Google Scholar] [CrossRef]
- Fujita, M.; Nakao, Y.; Matsunaga, S.; Seiki, M.; Itoh, Y.; Yamashita, J.; Van Soest, R.W.; Fusetani, N. Ageladine A: An antiangiogenic matrixmetalloproteinase inhibitor from the marine sponge Agelas nakamurai. J. Am. Chem. Soc. 2003, 125, 15700–15701. [Google Scholar] [CrossRef] [PubMed]
- Bickmeyer, U. The alkaloid Ageladine A, originally isolated from marine sponges, used for pH-sensitive imaging of transparent marine animals. Mar. Drugs. 2012, 10, 223–233. [Google Scholar] [CrossRef] [PubMed]
- Meketa, M.L.; Weinreb, S.M. Total synthesis of ageladine A, an angiogenesis inhibitor from the marine sponge Agelas nakamurai. Org. Lett. 2006, 8, 1443–1446. [Google Scholar] [CrossRef] [PubMed]
- Shengule, S.R.; Karuso, P. Concise total synthesis of the marine natural product ageladine A. Org. Lett. 2006, 8, 4083–4084. [Google Scholar] [CrossRef]
- Chen, X.; Du, Y.; Nan, J.; Zhang, X.; Qin, X.; Wang, Y.; Hou, J.; Wang, Q.; Yang, J. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS ONE 2013, 8, e63697. [Google Scholar] [CrossRef]
- Wang, H.Q.; Man, Q.W.; Huo, F.Y.; Gao, X.; Lin, H.; Li, S.R.; Wang, J.; Su, F.C.; Cai, L.; Shi, Y.; et al. STAT3 pathway in cancers: Past, present, and future. MedComm 2022, 3, e124. [Google Scholar] [CrossRef]
- Garbers, C.; Aparicio-Siegmund, S.; Rose-John, S. The IL-6/gp130/STAT3 signaling axis: Recent advances towards specific inhibition. Curr. Opin. Immunol. 2015, 34, 75–82. [Google Scholar] [CrossRef]
- Hirano, T. IL-6 in inflammation, autoimmunity and cancer. Int. Immunol. 2021, 33, 127–148. [Google Scholar] [CrossRef]
- Wong, A.L.A.; Hirpara, J.L.; Pervaiz, S.; Eu, J.Q.; Sethi, G.; Goh, B.C. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert Opin. Investig. Drugs 2017, 26, 883–887. [Google Scholar] [CrossRef]
- Johnson, D.E.; O’Keefe, R.A.; Grandis, J.R. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat. Rev. Clin. Oncol. 2018, 15, 234–248. [Google Scholar] [CrossRef]
- Darnell, J.E., Jr.; Kerr, I.M.; Stark, G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264, 1415–1421. [Google Scholar] [CrossRef] [PubMed]
- Zhong, Y.; Deng, L.; Shi, S.; Huang, Q.Y.; Ou-Yang, S.M.; Mo, J.S.; Zhu, K.; Qu, X.M.; Liu, P.Q.; Wang, Y.X.; et al. The novel STAT3 inhibitor WZ-2-033 causes regression of human triple-negative breast cancer and gastric cancer xenografts. Acta Pharm. Sin. 2022, 43, 1013–1023. [Google Scholar] [CrossRef] [PubMed]
- Yu, H.; Lee, H.; Herrmann, A.; Buettner, R.; Jove, R. Revisiting STAT3 signalling in cancer: New and unexpected biological functions. Nat. Rev. Cancer 2014, 14, 736–746. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Banwell, M.G.; Carr, P.D.; Willis, A.C. Modular Total Syntheses of the Alkaloids Discoipyrroles A and B, Potent Inhibitors of the DDR2 Signaling Pathway. Org. Lett. 2016, 18, 704–707. [Google Scholar] [CrossRef] [PubMed]
Compound | R1 | R2 | Salt Form | Log2 (Positive Control/Negative Control) a |
---|---|---|---|---|
14 | CH3 | / | −11.28 | |
15 | H | HCl | −10.99 | |
17 | H | HCl | −1.88 | |
19 | H | CF3COOH | −8.91 | |
25 | H | CF3COOH | −12.72 | |
27 | / | −2.90 | ||
28 | / | −11.85 |
Compound | IC50 ± SD (μM) a | |||
---|---|---|---|---|
A549 | DU145 | HELA | MDA-MB-231 | |
14 | 22.63 ± 1.59 | >25 | >25 | 19.48 ± 0.63 |
15 | 10.30 ± 0.82 | 16.69 ± 1.97 | 18.579 ± 0.85 | 14.72 ± 2.05 |
25 | 4.42 ± 0.42 | 8.73 ± 1.53 | 8.665 ± 0.34 | 5.60 ± 1.36 |
28 | >25 | >25 | >25 | >25 |
Compound | IC50 ± SD (μM) a | |
---|---|---|
HUVEC | BM | |
25 | 31.62 ± 0.83 | >50 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
He, N.; Li, L.; Li, R.; Zhang, S.-Q.; Wu, L.-H.; Guan, X.; Zhang, Q.-Y.; Jiang, T.; Yang, J.-B. A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects. Int. J. Mol. Sci. 2023, 24, 8859. https://doi.org/10.3390/ijms24108859
He N, Li L, Li R, Zhang S-Q, Wu L-H, Guan X, Zhang Q-Y, Jiang T, Yang J-B. A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects. International Journal of Molecular Sciences. 2023; 24(10):8859. https://doi.org/10.3390/ijms24108859
Chicago/Turabian StyleHe, Na, Li Li, Rui Li, Si-Qi Zhang, Li-Hong Wu, Xian Guan, Qian-Yue Zhang, Tao Jiang, and Jin-Bo Yang. 2023. "A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects" International Journal of Molecular Sciences 24, no. 10: 8859. https://doi.org/10.3390/ijms24108859